David A. Siegel Biomarin Pharmaceutical Inc Transaction History
Two Sigma Advisers, LP
- $42.5 Billion
- Q1 2024
A detailed history of David A. Siegel (Two Sigma Advisers, LP) transactions in Biomarin Pharmaceutical Inc stock. As of the latest transaction made, Two Sigma Advisers, LP holds 545,014 shares of BMRN stock, worth $44.9 Million. This represents 0.11% of its overall portfolio holdings.
Number of Shares
545,014
Previous 335,214
62.59%
Holding current value
$44.9 Million
Previous $32.3 Million
47.28%
% of portfolio
0.11%
Previous 0.08%
Shares
22 transactions
Others Institutions Holding BMRN
# of Institutions
623Shares Held
181MCall Options Held
1.73MPut Options Held
1.73M-
Primecap Management CO Pasadena, CA18.7MShares$1.54 Billion1.24% of portfolio
-
Vanguard Group Inc Valley Forge, PA18.1MShares$1.49 Billion0.03% of portfolio
-
Black Rock Inc. New York, NY14.5MShares$1.19 Billion0.03% of portfolio
-
Dodge & Cox San Francisco, CA14MShares$1.15 Billion0.75% of portfolio
-
State Street Corp Boston, MA6.9MShares$568 Million0.03% of portfolio
About BIOMARIN PHARMACEUTICAL INC
- Ticker BMRN
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 185,824,000
- Market Cap $15.3B
- Description
- BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-a...